Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive); By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 203

Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive); By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032

The global branded generics market size is expected to reach USD 410.86 billion by 2032, according to a new study by Polaris Market Research. The report “Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive); By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing rates of chronic diseases such as diabetes, hypertension, and cancer are driving the demand for drugs. Branded generics are becoming a popular choice for patients suffering from chronic illnesses as they offer a more affordable alternative to expensive brand-name drugs. The widespread use of generic drugs is another factor driving the branded generics market.

Generic drugs have become more widely accepted by both physicians and patients as they are equivalent in quality, safety, and efficacy to their brand-name counterparts. Government initiatives promoting the use of generic drugs to reduce overall healthcare costs are also driving the growth of the branded generics market. Governments worldwide are promoting the use of generic drugs to lower healthcare costs and increase access to affordable medicines for patients.

Growing burden of infectious and non-infectious diseases, along with the rising geriatric population, is expected to have a positive impact on the healthcare industry's growth. Chronic diseases such as diabetes, hypertension, and obesity are becoming more prevalent worldwide, and the geriatric population is more susceptible to these diseases.

As a result, the demand for healthcare services and products, including branded generics, is expected to increase significantly. According to an NCBI article, there were 537 million patients suffering from diabetes globally in 2021. Diabetes is a chronic disease that requires ongoing medical care and management. Branded generics are becoming a popular choice for diabetic patients as they offer a more affordable alternative to expensive brand-name drugs.

Hypertension is another chronic disease that is prevalent among the geriatric population. According to the World Health Organization (WHO), hypertension impacts 1 Bn people globally, and this is expected to rise to 1.5 Bn, by 2025. Branded generics offer an affordable treatment option for hypertension, which is driving their demand in the market.

Branded Generics Market Report Highlights

Anti-hypersensitive segment accounted for the largest share, owing to rise in cardiac ailments among geriatrics, and availability of low-cost alternatives

Oral segment accounted for the larger market share, owing to the advantages of oral based drug administration with minimal nursing experience, with high accept patient acceptability

Retail pharmacy is projected to experience larger revenue share, primarily due to increase in number of retail pharmacies in the developed markets

APAC is projected to register a higher growth rate in the study period, due to increase in preference of low-cost medicines

The global players include Teva Pharmaceutical, Lupin, Sanofi, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Endo International, GlaxoSmithKline, Pfizer, Apotex, and Viatris, Inc.

Polaris Market Research has segmented the branded generics market report based on drug class, application, route of administration, by distribution channel, and region:

Branded Generics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Alkylating Agents

Antimetabolites

Hormones

Anti-Hypertensive

Lipid Lowering Drugs

Anti-Depressants

Anti-Psychotics

Anti-Epileptics

Others

Branded Generics, Application Outlook (Revenue - USD Billion, 2019 - 2032)

Oncology

Cardiovascular Diseases

Neurological Diseases

Gastrointestinal Diseases

Dermatological Diseases

Acute and Chronic Pain

Others

Branded Generics, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Topical

Oral

Parenteral

Others

Branded Generics, Distribution Channel Industry Outlook (Revenue - USD Billion, 2019 - 2032)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Branded Generics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa